Bacterial Toxin Targets Discovered
News Nov 25, 2014
Research that provides a new understanding of how bacterial toxins target human cells is set to have major implications for the development of novel drugs and treatment strategies.
Cholesterol-dependent cytolysins (CDCs) are toxins produced by major bacterial pathogens, most notably Streptococcus pneumoniae and group A streptococci, which collectively kill millions of people each year.
The toxins were thought to work by interacting with cholesterol in target cell membranes, forming pores that bring about cell death.
Published today in the prestigious journal Proceedings of the National Academy of Sciences, the research is an international collaboration between the University of Adelaide's Professor James Paton and Professor Michael Jennings from Griffith University, and collaborators at the University of Queensland and Department of Microbiology, New York University School of Medicine.
The team has, for the first time, shown that these toxins require binding to specific glycans (sugar structures) on the cell surface for efficient targeting of the host.
This explains why some cell types are more susceptible to the toxins than others, and also provides opportunities to develop novel drugs capable of blocking toxin-glycan interactions, thereby protecting host cells from toxin-mediated damage.
Professor Jennings, Deputy Director of the Institute for Glycomics at Griffith University, says these findings open up a completely novel approach to developing drugs which may block toxin action.
"Understanding how toxins target particular cells in the human body is the first step in understanding their mechanism of action and how to block them from causing cell death."
Professor Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases, says: "Interactions between CDCs and glycan receptors on immune cells also explains why these toxins have additional effects on host responses to infection, which enable the pathogenic bacteria to 'fly under the radar' of host immune defences."
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.